Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis

ConclusionPatients with a poor PS, such as those described here, may still have meaningful clinical responses to cancer treatments targeting oncogenic drivers. More studies evaluating PARPi ’s beyondgBRCA1/2 mutations and in sub-optimal PS would help identify patients who may benefit from these therapies.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research